Novavax shares up on fourth quarter earnings beat

Investing.com

02-27

Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.

The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.

Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi (NASDAQ:SNY) starting with the 2025-2026 season.

The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.

The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.

Related Articles

Novavax shares up on fourth quarter earnings beat

India's economic growth faces challenges, IMF suggests reforms

Goldman Sachs tweaks its diversity policy

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2514438388"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514438388\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514438388?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 22:25","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2514438388","market":"us","top_or_hot":-1,"title":"Novavax shares up on fourth quarter earnings beat","media":"Investing.com","content":"<html><body><p>Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.</p>\n<p>The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.</p>\n<p>Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> (NASDAQ:SNY) starting with the 2025-2026 season. <br/><br/>The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.</p>\n<p>The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.</p>\n<p>Related Articles</p>\n<p>Novavax shares up on fourth quarter earnings beat</p>\n<p>India's economic growth faces challenges, IMF suggests reforms</p>\n<p>Goldman Sachs tweaks its diversity policy</p>\n</body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Novavax shares up on fourth quarter earnings beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares up on fourth quarter earnings beat\n</h2>\n<h4 class=\"meta\">\n\n\n2025-02-27 22:25 GMT+8   <a href=\"https://finance.yahoo.com/news/novavax-shares-fourth-quarter-earnings-142515939.html\"><strong>Investing.com</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is ...</p>\n<a href=\"https://finance.yahoo.com/news/novavax-shares-fourth-quarter-earnings-142515939.html\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://finance.yahoo.com/news/novavax-shares-fourth-quarter-earnings-142515939.html","article_id":"2514438388","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514438388","pubTimestamp":1740666315,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Investing.com --Shares of Novavax  rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.The vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.Novavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi  starting with the 2025-2026 season. The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk , a move expected to reduce annual costs by about $80 million.The company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacob","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药","SNY":"赛诺菲安万特"},"translate_title":"Novavax股价因第四季度盈利超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":1,"SNY":0.9},"content_text":"Investing.com -- Shares of Novavax (NASDAQ:NVAX) rose about 1.75% in premarket trading after reporting a smaller-than-expected quarterly loss but it missed revenue estimates. The company is transitioning away from direct commercialization of its COVID-19 vaccine.\nThe vaccine maker posted a fourth-quarter loss per share of $0.51, beating analysts’ expectations of a 60-cent loss on each share. Revenue came in at $88.31 million, below the consensus estimate of $102.74 million.\nNovavax said it was transitioning away from commercial responsibilityof its COVID-19 vaccine, Nuvaxovid, giving it to Sanofi (NASDAQ:SNY) starting with the 2025-2026 season. The company also secured a $50 million milestone payment under its Sanofi agreement and completed the $200 million sale of its Czech Republic manufacturing facility to Novo Nordisk (NYSE:NVO), a move expected to reduce annual costs by about $80 million.\nThe company ended 2024 with over $1 billion in cash and accounts receivables and provided 2025 financial guidance. CEO John C. Jacobs said Novavax is shifting its focus toward pipeline expansion and partnerships for its vaccine candidates and adjuvant technology.\nRelated Articles\nNovavax shares up on fourth quarter earnings beat\nIndia's economic growth faces challenges, IMF suggests reforms\nGoldman Sachs tweaks its diversity policy","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}